Fig. 3.

Central illustration: comparing the efficacy of prasugrel and ticagrelor among acute coronary syndrome patients*. The graphical summary of the study. From the 11 eligible RCTs, we identified 6,098 patients with acute coronary syndrome who were randomized to either prasugrel or ticagrelor with a weighted mean follow-up of 11 months. There is no difference in the primary composite endpoint of myocardial infarction, stroke, and cardiovascular death between the use of prasugrel and ticagrelor after analyzing the outcome data using the random-effects model (RR = 1.17; 95% CI = 0.96–1.42; p = 0.12, I² = 0%). *“Atherosclerosis image: Freepik.com designed by brfx.” This cover has been designed using resources from Freepik.com; ^†f/u = follow-up; ^‡MI, myocardial infarction; ^§BARC, Bleeding Academic Research Consortium; ^||Pras, prasugrel; ^¶Tic, ticagrelor.